St. Eugenio Hospital

Futó vizsgálatok

• Toboroz

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· 3. fázis· Incyte Corporation· Forrás

• Toboroz

  European Myeloma Network (EMN) Sample Project

  NCT06237803· European Myeloma Network B.V.· Forrás

• Toboroz

  Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

  NCT03994471· 3. fázis· Iperboreal Pharma Srl· Forrás

• Toboroz

  Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

  NCT05924100· 2. fázis· Associazione Qol-one· Forrás

• Még nem toboroz

  Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell Transplantation (allo-SCT) in Acute Myeloid Leukemia (AML) patients (≥40 <65years)

  2024-520326-11-00· 2. fázis· Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia· Forrás

• Toboroz

  Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

  NCT06516406· IRCCS Azienda Ospedaliero-Universitaria di Bologna· Forrás

• Fut, nem toboroz

  A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

  NCT04680052· 3. fázis· Incyte Corporation· Forrás

• Fut, nem toboroz

  Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

  NCT04603495· 3. fázis· Novartis Pharmaceuticals· Forrás

• Toboroz

  A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)

  NCT05001087· Fondazione EMN Italy Onlus· Forrás

• Fut, nem toboroz

  An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

  NCT04717414· 3. fázis· Celgene· Forrás

• Toboroz

  NobleStitch EL STITCH Trial is a PFO Comparative Trial

  NCT04339699· Nobles Medical Technologies II Inc· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Mielóma multiplex2 toboroz
• Mieloproliferatív neopláziák2 toboroz
• Akut mieloid leukémia (AML)1 toboroz
• Krónikus vesebetegség1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Stroke (szélütés)1 toboroz

Lezárt vizsgálatok

• Toboroz

  A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressive B-cell Non-Hodgkin Lymphoma.

  NCT06230224· 3. fázis· Regeneron Pharmaceuticals Inc.· Forrás

• Lezárult

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  NCT03301220· 3. fázis· Janssen Research & Development, LLC· Forrás

• Lezárult

  A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

  NCT03106324· Celgene· Forrás

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Krónikus mieloid leukémia (CML)8 munka · 0 vizsgálat
• Mieloproliferatív neopláziák7 munka · 4 vizsgálat